Direction at a glance
Rare cures after donor stem-cell transplantation prove that durable HIV remission is biologically possible, but transplantation risk makes that route inappropriate for routine HIV care. Research therefore explores safer engineered autologous cells and multilayered resistance.
What the evidence establishes
- CCR5 disruption can make susceptible cells resistant to many, but not all, HIV variants.
- Donor transplantation cures occurred in people treated for life-threatening cancers, not as standard HIV therapy.
- Preclinical work is combining CCR5 knockout with antibody secretion in engineered blood stem cells.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
Stem-cell transplantation carries major morbidity and mortality. Preclinical engineering results must not be presented as a routine clinical cure.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
CCR5 knockout and antibody secretion in engineered blood stem cellsNature Communications · Primary research · Access checked 18 Aug 2026
↗02NIH Strategic Plan for HIV and HIV-Related Research, updated 2025NIH Office of AIDS Research · Research strategy · Access checked 18 Aug 2026
↗